Abstract. Class III β-tubulin (TUBB3) is a component of microtubules of neuronal cells that is upregulated in various cancer entities. To better understand the role of TUBB3 in upper gastrointestinal tract cancer types, the present study assessed TUBB3 expression in tissue microarrays including 189 gastric and 428 esophageal cancer. TUBB3 expression was detected in 62.4% of gastric cancer, 73.8% of esophageal adenocarcinoma and 88.7% of esophageal squamous cell cancer, while control samples of normal esophageal and gastric epithelium were TUBB3-negative. TUBB3 positivity was not associated with the International Union Against Cancer classification, World Health Organization grading, lymph node involvement or distant metastasis in any entity. Of note, TUBB3 expression was associated with tumor localization and prognosis in gastric cancer, with the tumor stage in esophageal adenocarcinoma, and with the resection margin in esophageal squamous cell cancer. In conclusion, the substantial rate of positivity for TUBB3 already in early stages of gastric cancer in combination with the lack of a further increase in frequency with tumor stage, may suggest, that TUBB3 upregulation is rather relevant for cancer development than for cancer progression. TUBB3 might be a suitable prognostic biomarker in gastric cancer types.
Introduction
Upper gastrointestinal cancers are among the leading causes of cancer-associated mortality worldwide. Approximately 1.5 million people are diagnosed with gastric and esophageal cancer each year (1, 2) . Despite improvements in diagnosis and therapy in the last decades, the outcome for patient with gastric and esophageal cancers remains poor with 5-year survival rates not exceeding 20-30% in Western societies (3) (4) (5) . The molecular mechanisms underlying carcinogenesis remain largely elusive. Accordingly, molecular markers allowing for prediction of the clinical course of these diseases are currently lacking. Hence, there is a high demand for molecular markers to predict tumor aggressiveness and response to therapy for these cancer types.
Microtubules are multifunctional cytoskeletal proteins involved in numerous cellular processes including maintenance of cell shape, intracellular transport and chromosome segregation during mitosis and meiosis. Microtubules are composed of polymers of α-and β-tubulin heterodimers. Class III β-tubulin (TUBB3) is typically expressed in cells of neuronal origin, where it contributes to the formation of dynamic microtubules essential for neurite formation and maintenance (6) . Several lines of evidence suggest that TUBB3 also has an important role in tumor development. In fact, overexpression of TUBB3 has been linked to poor clinical outcome in numerous epithelium-derived tumor types, including non-small cell lung (7), bladder (8) , breast (9), ovarian (10) and prostate cancer (11) . Several studies analyzing gastric and/or esophageal cancer specimens (n=29-149) have also suggested clinically relevant roles of TUBB3 expression levels in upper gastrointestinal cancer (12) (13) (14) . Of note, elevated levels of TUBB3 expression have been associated with a reduced response to taxane-based microtubule-targeting cancer therapy (7, (10) (11) (12) 15 (16) . Data on neoadjuvant or adjuvant cytotoxic therapy regimens or response to treatment were unavailable. The TMA manufacturing was performed as described in previous studies (17, 18) . Each TMA block contained internal controls of normal esophageal and gastric tissue taken from the same patient cohort.
The Ethics Committee of the Ärztekammer Hamburg approved the present study (no. WF-049/09). According to local laws (HmbKHG §12a), informed consent was not required. Patient records/information were anonymized prior to analysis. All work was performed in compliance with the Helsinki Declaration.
Immunohistochemistry. TUBB3 staining and scoring was performed as described in a previous study (9) . The recombinant rabbit monoclonal anti-TUBB3 antibody clone EPR1568Y was used at a dilution 1:150 of (cat. no. Statistical analysis. JMP 12.0 software (SAS Institute Inc., Carey, NC, USA) was used to calculate contingency tables and P-values with the chi-squared (likelihood) test. Kaplan-Meier curves were drawn and significant differences between groups were assessed by the log-rank method. Cox regression analysis was used to compare hazard ratios in univariate and multivariate models. P≤0.05 was considered to indicate a statistically significant difference.
Results

TUBB3-staining.
The results of the TMA analysis were interpretable for a total of 189/230 (82%) of gastric and 431/594 (73%) of esophageal tumor samples. In the non-informative TMA spots (18% for gastric cancer and 27% for esophageal cancer), the tissue sample was lacking or no unequivocal cancer tissue was observed. Normal gastric and esophageal tissues exhibited no staining under the selected experimental conditions. Fig. 1 shows representative images of normal gastric and esophageal tissue.
TUBB3-expression in gastric cancer.
In gastric cancer, positive staining for TUBB3 was detected in 118 of 189 analyzable spots (62.4%) and was rated weak in 11.1%, moderate in 18% and strong in 33.3% of these samples. Representative images of TUBB3 staining in gastric cancers are given in Fig. 2 Fig. 3 . In esophageal adenocarcinomas, no association between TUBB3 and UICC stage, WHO grading, or the presence of lymph node or distant metastasis was identified (P>0.05 each; Table II ). Only the tumor stage was significantly associated with TUBB3 expression (P=0.0289; Table II ). In esophageal squamous cell carcinomas, only the resection margin Table I . Association between TUBB3 expression and gastric cancer phenotype. was significantly associated with TUBB3 (P<0.05; Table III ). For the association of TUBB3 with the tumor stage a similar trend as in the adenocarcinomas was observed.
Kaplan-meier analysis. Follow-up data were available from 93 patients with gastric cancer and 393 patients with esophageal cancer (204 adenocarcinomas and 189 squamous cell cancers) with interpretable TUBB3 staining on the TMA. While in gastric cancer TUBB3 expression was associated with shorter overall survival (Fig. 4A and B) , TUBB3 expression had no impact on the survival of esophageal cancer patients (P>0.05; Fig. 4C and D) .
Multivariate analysis.
Hazard ratios for overall survival were calculated. In gastric cancer, TUBB3 expression was an independent risk factor for shorter survival (P<0.05; Table IV ).
Discussion
The results of the present study demonstrate that TUBB3 is frequently expressed in upper gastrointestinal cancer types associated with patient prognosis only in gastric cancer, but not in esophageal adenocarcinoma and esophageal squamous cell cancer.
TUBB3 expression was identified in 62.4% of the 189 gastric cancer tissues, in 73.8% of the 233 esophageal adenocarcinoma tissues and 88.7% of the 195 esophageal squamous cell cancer tissues in the present study, but was undetectable in the respective normal tissue samples. In principle, these immunohistochemical results are compatible with earlier studies on these tumor types. This particularly applies to gastric tumors, where two earlier studies on gastric cancer tissues (n=115 and 146) reported comparable data, Table II . Association between TUBB3 expression and esophageal adenocarcinoma phenotype.
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No. Table III . Association between TUBB3 expression and esophageal squamous cell cancer phenotype. namely detectable TUBB3 expression in 36 and 53% of tumor samples (12, 19) . The results of two earlier studies on esophageal squamous cell cancers were more conflicting, reporting TUBB3-positive rates of 7 and 95%, respectively (14, 20) . The striking discrepancy of these data is typical for studies using 'homemade' immunohistochemical protocols. It is known, that the use of different antibodies, immunohistochemistry protocols and scoring criteria can result in discrepant data (21) . The important function of TUBB3 in the maintenance of the dynamic plasticity of microtubules (22,23) -a prerequisite for cell motility, invasive growth, mitotic spindle orientation, and cell cycle progression-would be consistent with a significant role for TUBB3 in tumor development and progression. The high frequency of detectable TUBB3 staining in early gastric cancer in combination with the lack of a further elevation in frequency with the tumor stage increasing, may suggest that up regulation of TUBB3 is an event in carcinogenesis of gastric cancer and has a relevance in cancer development rather than cancer progression. Other studies have failed to identify an association between TUBB3 expression and clinico-pathological parameters or patient prognosis in gastric or esophageal carcinomas (12, 19, 20) . In the present study, analysis of a much larger number of tumors did reveal a significant association with patient outcome in gastric cancer providing some arguments for TUBB3 testing. This is in line to the results on the predictive value of TUBB3 in a variety of other cancer types. Using the same staining protocol, another recent study by our group identified the prognostic value of TUBB3 in prostate cancer, which was independent of established pre-and post-operatively available prognostic features (24) . Others studies have reported TUBB3 overexpression is linked to late tumor stage and poor prognosis in breast (25) , lung (26, 27) , colon (28) , ovarian (10, 29, 30) , prostate (11, 24) and several neurological cancers (28) .
The present study was a retrospective study. Thus it remains to be seen whether the prognostic value of TUBB3 expression in gastric cancer can be validated in a prospective study.
In summary, the results of the present study demonstrate that TUBB3 is frequently expressed in upper gastrointestinal cancer types, including esophageal and gastric tumors. For gastric cancer, TUBB3 expression might be a prognostic factor.
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